COVID-19 is an emerging, rapidly evolving situation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
NCL News Archive
Tuesday, July 23, 2019
Facilitating API Delivery with Nanoscale Solutions
The July issue of Pharmaceutical Technology highlights nanotechnology with interviews from Young-Ho Song, a research fellow at Pfizer Oncology, and NCL’s Stephan Stern. The article, written by Cynthia Challener, touches on some of the most promising avenues for nanotech—improving the therapeutic potential of existing drugs, resurrecting previously failed drugs, developing generics of current... View Post
Tuesday, July 23, 2019
Bioequivalence Studies: Doxil vs. Sun Pharma and Abraxane vs. Genexol-PM
The NCL recently completed a 2.5 year interagency collaboration with the US Food and Drug Administration (FDA) to evaluate the bioequivalence of marketed nanomedicines. The complexity of nanomedicine drug formulations poses unique scientific challenges. And, with the influx of generic versions of several nanomedicines now nearing clinical evaluation, these formulations pose unique regulatory... View Post
Wednesday, May 15, 2019
Identifying the Risk of Infusion Reactions
The NCL has just launched a new Technical Service to assess the potential for infusion reactions. Systemic administration of nanomedicines (and other therapies) have the potential to cause infusion reactions in patients, which often delays or halts their clinical translation. These reactions can manifest as fevers, chills, rigors, rashes, chest or back pain, or difficulty breathing, and, in... View Post
Tuesday, April 9, 2019
NANOBIOTIX Announces First Ever Radioenhancer to Receive European Market Approval
Former NCL Collaborator NANOBIOTIX recently announced European market approval for their formulation Hensify® (NBTXR3). Per the press release:
Hensify®(NBTXR3) received European market approval (CE mark) enabling commercialization in 27 European Union countries for the treatment of locally advanced soft tissue sarcoma Hensify®--a first-in-class radioenhancer--offers cancer patients an... View PostThursday, April 4, 2019
New Mechanistic Immunotoxicology Protocols
NCL's Immunology team has put together a series of new protocols which probe various immunotoxicology aspects of nanomedicines. The 7 new protocols have been published on the NCL Assay Cascade Protocols webpage and are available for download. They include:
ITA-26: Detection of Intracellular Complement Activation in Human T Lymphocytes
The complement... View Post
Tuesday, March 5, 2019
CRS Nanomedicine and Nanoscale Delivery Webinar
The Controlled Release Society’s (CRS) Nanomedicine and Nanoscale Delivery Focus Group will host their first webinar in March, given by NCL Director, Scott McNeil. This webinar will highlight the unique challenges of nanomedicine development, including the complex characterization requirements for these formulations and the hurdles of regulatory review. Having characterized more than 400... View Post
Tuesday, March 5, 2019
December 2018 Awardees Announced
The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post
Friday, February 1, 2019
Position Available: Research Associate, Physicochemical Characterization
The Nanotechnology Characterization Lab (NCL) provides nanotechnology formulation and characterization services for universities, the pharmaceutical industry and other government programs. Since our founding in 2004, the NCL has characterized more than 400 different nanomedicines for more than 100 organizations worldwide. We are currently seeking a Research Associate to join... View Post
Friday, February 1, 2019
Position Available: Scientist, Physicochemical Characterization
The Nanotechnology Characterization Lab (NCL) provides nanotechnology formulation and characterization services for universities, the pharmaceutical industry and other government programs. Since our founding in 2004, the NCL has characterized more than 400 different nanomedicines for more than 100 organizations worldwide. We are currently seeking a Scientist to join our... View Post
Friday, February 1, 2019
JoVE Publication on LAL Assay
Endotoxin testing has been one of the most commonly requested needs among nanotech researchers applying to the NCL. Dr. Marina Dobrovolskaia, Sr. Principal Scientist, has spent more than a decade studying the intricacies of endotoxin detection in nanoformulations. Much of her work has focused on assessing the pros and cons of the various detection methods and determining ways to overcome... View Post